Brand-Generic Patent Settlements Reported to the US Federal Trade Commission

Importance Generic competition is the most important factor in reducing spending on brand-name prescription drugs in the US. Yet, the timing of generic entry is often determined by confidential settlements resolving patent litigation between brand-name and generic manufacturers. Objective To characterize brand-generic patent settlements using publicly available summary information from the US Federal Trade Commission (FTC). Design and Setting This case-series study reviewed all published FTC reports on brand-generic patent settlements covering fiscal years 2004-2021 using a standardized data-extraction protocol. The reports were downloaded and the analysis conducted from September 2025 through August 2026. Main Outcomes and Measures Characteristics and frequency of settlements, including the presence of restrictions on generic entry; compensation from the brand-name manufacturer to the generic company, including litigation fees; whether the generic manufacturer obtained patent rights outside the scope of those litigated; and provisions allowing the agreed-upon generic entry date to move forward if certain events occurred, such as another generic company entering the market (acceleration clauses). Results In 18 FTC reports, the median number of settlements was 150.5 per year (IQR, 66.5-197.75). A total of 2405 settlements were reported during the study period, with 2064 (86%) including restrictions on generic entry. Among settlements restricting entry, 394 (19%) involved explicit compensation and 100 (5%) involved additional forms of possible compensation from the brand-name to the generic manufacturer. From 2016 through 2021, 1178 of 1301 settlements (91%) granted generics rights to patents not asserted in litigation and 1001 of 1301 settlements (77%) included acceleration clauses. Conclusions and Relevance These findings suggest that settlement agreements frequently contain provisions that may influence the timing of generic entry beyond the strength of the patents at issue. Greater transparency regarding these agreements could improve oversight of anticompetitive conduct.